| Name | Title | Contact Details |
|---|
Immatics Biotechnologies is a clinical-stage biopharmaceutical company leading the development of advanced immunotherapies that are active against cancer. Cancer immunotherapy is still severely constrained by the lack of novel targets. Immatics overcomes this by applying its target discovery engine XPRESIDENT® to identify and validate antigens specific to cancer cells. These antigens, also called Tumor-Associated Peptides (TUMAPs), are able to activate T cells which are responsible for identifying and destroying cancer cells. These well characterized TUMAPs can be used as targets for all of the most promising cancer immunotherapy approaches including Adoptive Cell Therapies (ACT), soluble T Cell Receptors (TCRs), Antibodies and Cancer Vaccines. The US based Immatics US, Inc., launched in Aug. 2015, is focused on the development of three ACT approaches for the treatment of tumors with high unmet medical needs: ACTolog™, ACTengine™, and ACTallo™ in close collaboration with leading scientists at the MD Anderson Cancer Center, who contribute their long-term ACT expertise. The first ACT products are expected to enter the clinic in 2016. Immatics signed a strategic cancer immunotherapy collaboration with Roche in November 2013 to research, develop and commercialize a number of new cancer peptide antigen-based immunotherapies. In addition, Immatics is engaged in the development of soluble T-cell receptor (sTCR) approaches as well as monoclonal antibodies (mABs) directed towards XPRESIDENT® targets. The latter will be pursued in a strategic alliance with MorphoSys. Immatics is further conducting the clinical development of fully personalized therapeutic cancer vaccines, Glioma Actively Personalized VAccine Consortium (GAPVAC; an EU-funded consortium) in collaboration with BioNTech. Immatics GmbH is based in Tübingen, Germany, with a headcount of approximately 90 people. Immatics US, Inc. is based in Houston, Texas, USA, and currently employs approximately 15 people.
We are harnessing the power of the immune system to target some of the most challenging solid tumor malignancies.
Ignyta, located in San Diego, California, is a biotechnology company developing precision medicine with integrated Rx/Dx solutions for cancer patients. Its goal is to discover and develop revolutionary new drugs that target activated genes in cancer cells for the customized treatment of cancer patients. The company's present focus is on the development of RXDX-101, its proprietary oral tyrosine kinase inhibitor that targets solid tumor indications, and advancing its novel Spark discovery programs that leverage its proprietary cancer genomic and epigenomic knowledge bases
Millendo Therapeutics is focused on developing novel treatments for endocrine diseases. Our mission is to build a leading endocrine company that creates distinct and transformative treatments for a wide range of diseases where there is a significant unmet medical need. We are currently advancing two product candidates: livoletide (AZP-531) and nevanimibe (ATR-101). Livoletide is being developed for Prader-Willi syndrome while nevanimibe is in development for the treatment of two different orphan adrenal diseases: Classic Congenital Adrenal Hyperplasia (CAH) and Endogenous Cushing`s Syndrome (CS).
Epic Sciences, Inc. is developing novel diagnostics to personalize and advance the treatment and management of cancer. Epic`s mission is to enable the rapid and non-invasive detection of genetic and molecular changes in cancer throughout a patient`s journey. The company was founded on a powerful platform to identify and characterize rare cells, including circulating tumor cells (CTCs). Our technology helps match patients to targeted therapies and monitor for drug resistance, so that the best treatment path can be chosen at every clinical decision point. Today, we partner with leading pharmaceutical companies and major cancer centers around the world. Epic`s goal is to commercialize our technology to increase the success rate of cancer drugs in clinical trials and improve patient outcomes by providing physicians with real-time information to guide treatment choices.